medical affairs strategy

By Jacob Presson, Research Analyst In light of the coming American Society for Clinical Oncology (ASCO) annual meeting, many companies are scrambling to get their medical publications out by the conference deadline. One of the biggest contributions...

By Sarah Ray, Research Analyst Drug companies are reaching beyond specialists when targeting medical leaders to further develop their existing products.  Among 36 companies recently surveyed, nearly four-fifths targeted multiple types of key opinion...

Over the past several years, we have seen a slow shift among regulatory affairs and compliance groups in the pharmaceutical industry as these groups move under medical affairs oversight. This hasn’t been a surprise among many industry observers, but it hasn’t...

Marketing and commercial teams get a lot of the credit for a successful product launch, but medical affairs teams are typically buzzing with activity in the months (sometimes even years) preceding drug approval.  As the official communication channel between a...

Cutting Edge Information recently conducted research among pharmaceutical medical affairs groups that looked at physician-interaction database ownership.  The research revealed that ownership of these databases varies among the surveyed companies.  Global groups...

Drug companies’ increased pharmacovigilance activities highlight the importance of both clinical data and adverse events reporting.  The World Health Organization (WHO) estimates that adverse drug reactions (ADRs) represent between the fourth- and sixth-leading...

Although marketing and market access functions may not support a developing drug until Phase 2 or even later, companies need to coordinate between several different teams as products move through different development stages beginning in the pre-clinical stage....

Within companies’ medical affairs groups, medical information subfunctions disseminate information quickly across consumer and healthcare practitioner audiences alike.  However, US companies rely on different-sized medical information teams to fulfill these...

Regardless of company size, establishing operations to support expansions in new territories has a big impact on existing organizational structures.  The question often rests on how the subsidiary will be connected to the headquarters. Will it be a centralized...

Pharmaceutical companies may not take the Hippocratic Oath, but, through dedicated pharmacovigilance programs, companies ensure that drug safety remains a top priority among their medical affairs responsibilities.  Within companies’ medical affairs teams, evaluating...